Skip to main content
Erschienen in: Annals of Surgical Oncology 9/2012

01.09.2012 | Hepatobiliary Tumors

Prognostic Significance of Antithrombin III Levels for Outcomes in Patients with Hepatocellular Carcinoma After Curative Hepatectomy

verfasst von: Hiroshi Iwako, MD, Hirotaka Tashiro, MD, Hironobu Amano, MD, Yoshisato Tanimoto, MD, Akihiko Oshita, MD, Tsuyoshi Kobayashi, MD, Shintaro Kuroda, MD, Hirofumi Tazawa, MD, Junko Nambu, MD, Yoshihiro Mikuriya, MD, Tomoyuki Abe, MD, Hideki Ohdan, MD

Erschienen in: Annals of Surgical Oncology | Ausgabe 9/2012

Einloggen, um Zugang zu erhalten

Abstract

Background

Although several studies have shown that serum antithrombin III (ATIII) has anti-inflammatory effects, the prognostic value of ATIII in HCC is unknown. We investigated the influence of preoperative ATIII levels on the outcome of patients who underwent hepatectomy for hepatocellular carcinoma (HCC).

Methods

Data from 440 patients (314 patients with ATIII ≥70 % and 126 patients with ATIII <70 %) who underwent curative hepatectomy for HCC were retrospectively collected and analyzed. To overcome bias due to the different distribution of covariates for the 2 groups, propensity score matching was performed on the patients, and outcomes were compared.

Results

The propensity score analysis revealed that 65 patients with ATIII of ≥70 % (group 1) and 65 patients with ATIII of <70 % (group 2) had the same preoperative and operative characteristics (excluding the ATIII level). The overall survival rate and the disease-free survival rate was significantly higher in group 1 than in group 2 (P = 0.005 and 0.011, respectively). Multivariate analysis showed that ATIII was a significant favorable factor for overall survival and disease-free survival of patients with HCC after curative hepatectomy.

Conclusions

The prognosis of patients with HCC was found to be associated with preoperative antithrombin III levels. ATIII may be useful for predicting outcomes of patients with HCC after curative hepatectomy.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Fan ST, Lo CM, Poon RT, Yeung C, Liu CL, Yuen WK, et al. Continuous improvement of survival outcomes of resection of hepatocellular carcinoma: a 20-year experience. Ann Surg. 2011;253:1–14.CrossRef Fan ST, Lo CM, Poon RT, Yeung C, Liu CL, Yuen WK, et al. Continuous improvement of survival outcomes of resection of hepatocellular carcinoma: a 20-year experience. Ann Surg. 2011;253:1–14.CrossRef
2.
Zurück zum Zitat Portolani N, Coniglio A, Ghidoni S, Giovanelli M, Benetti A, Tiberio GAM, et al. Early and late recurrence after liver resection for hepatocellular carcinoma: prognostic and therapeutic implications. Ann Surg. 2006;243:229–35.PubMedCrossRef Portolani N, Coniglio A, Ghidoni S, Giovanelli M, Benetti A, Tiberio GAM, et al. Early and late recurrence after liver resection for hepatocellular carcinoma: prognostic and therapeutic implications. Ann Surg. 2006;243:229–35.PubMedCrossRef
3.
Zurück zum Zitat Rosenberg RD. Biochemistry of heparin antithrombin interaction, and the physiologic role of this natural anticoagulant mechanism. Am J Med. 1989;87:2S–9S.PubMedCrossRef Rosenberg RD. Biochemistry of heparin antithrombin interaction, and the physiologic role of this natural anticoagulant mechanism. Am J Med. 1989;87:2S–9S.PubMedCrossRef
4.
Zurück zum Zitat Larsson H, Sjöblom T, Dixelius J, Östman A, Ylinenjärvi K, Björk I, et al. Antiangiogenic effects of latent antithrombin through perturbed cell-matrix interactions and apoptosis of endothelial cells. Cancer Res. 2000;60:6723–9.PubMed Larsson H, Sjöblom T, Dixelius J, Östman A, Ylinenjärvi K, Björk I, et al. Antiangiogenic effects of latent antithrombin through perturbed cell-matrix interactions and apoptosis of endothelial cells. Cancer Res. 2000;60:6723–9.PubMed
5.
Zurück zum Zitat Kisker O, Onizuka S, Banyard J, Komiyama T, Becker CM, Achilles EG, et al. Generation of multiple angiogenesis inhibitors by human pancreatic cancer. Cancer Res. 2001;61:7298–304.PubMed Kisker O, Onizuka S, Banyard J, Komiyama T, Becker CM, Achilles EG, et al. Generation of multiple angiogenesis inhibitors by human pancreatic cancer. Cancer Res. 2001;61:7298–304.PubMed
6.
Zurück zum Zitat Buller HR, Boon TA, Henny CP, Dabhoiwala NF, ten Cate JW. Estrogen-induced deficiency and decrease in antithrombin III activity in patients with prostatic cancer. J Urol. 1982;128:72–4.PubMed Buller HR, Boon TA, Henny CP, Dabhoiwala NF, ten Cate JW. Estrogen-induced deficiency and decrease in antithrombin III activity in patients with prostatic cancer. J Urol. 1982;128:72–4.PubMed
7.
Zurück zum Zitat Honegger H, Anderson N, Hewitt LA, Tullis JL. Antithrombin III profiles in malignancy, relationship primary tumors and metastatic sites. Thromb Haemost. 1981;46:500–3.PubMed Honegger H, Anderson N, Hewitt LA, Tullis JL. Antithrombin III profiles in malignancy, relationship primary tumors and metastatic sites. Thromb Haemost. 1981;46:500–3.PubMed
8.
Zurück zum Zitat Mulder AB, Zwaveling JH, Smid WM, Maring JK, van Ginkel RJ, Girbes AR, et al. Augmented procoagulant activity in cancer patients treated with recombinant interferon-gamma in addition to recombinant tumor necrosis factor-alpha and melphalan. Thromb Haemost. 1996;76:897–901.PubMed Mulder AB, Zwaveling JH, Smid WM, Maring JK, van Ginkel RJ, Girbes AR, et al. Augmented procoagulant activity in cancer patients treated with recombinant interferon-gamma in addition to recombinant tumor necrosis factor-alpha and melphalan. Thromb Haemost. 1996;76:897–901.PubMed
9.
Zurück zum Zitat Itamoto T, Katayama K, Nakahara H, Tashiro H, Asahara T. Autologous blood storage before hepatectomy for hepatocellular carcinoma with underlying liver disease. Br J Surg. 2003;90:23–8.PubMedCrossRef Itamoto T, Katayama K, Nakahara H, Tashiro H, Asahara T. Autologous blood storage before hepatectomy for hepatocellular carcinoma with underlying liver disease. Br J Surg. 2003;90:23–8.PubMedCrossRef
10.
Zurück zum Zitat Makuuchi M, Kosuge T, Takayama T, Yamazaki S, Kakazu T, Miyagawa S, et al. Surgery for small liver cancers. Semin Surg Oncol. 1993;9:298–304.PubMedCrossRef Makuuchi M, Kosuge T, Takayama T, Yamazaki S, Kakazu T, Miyagawa S, et al. Surgery for small liver cancers. Semin Surg Oncol. 1993;9:298–304.PubMedCrossRef
11.
Zurück zum Zitat Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg. 1973;60:646–9.PubMedCrossRef Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg. 1973;60:646–9.PubMedCrossRef
12.
Zurück zum Zitat Makuuchi M, Hasegawa H, Yamazaki S. Ultrasonically guided subsegmentectomy. Surg Gynecol Obstet. 1985;161:346–50.PubMed Makuuchi M, Hasegawa H, Yamazaki S. Ultrasonically guided subsegmentectomy. Surg Gynecol Obstet. 1985;161:346–50.PubMed
13.
Zurück zum Zitat Yamamoto M, Takasaki K, Ohtsubo T, Katsuragawa H, Fukuda C, Katagiri S. Effectiveness of systematized hepatectomy with Glisson’s pedicle transection at the hepatic hilus for small nodular hepatocellular carcinoma: retrospective analysis. Surgery. 2001;130:443–8.PubMedCrossRef Yamamoto M, Takasaki K, Ohtsubo T, Katsuragawa H, Fukuda C, Katagiri S. Effectiveness of systematized hepatectomy with Glisson’s pedicle transection at the hepatic hilus for small nodular hepatocellular carcinoma: retrospective analysis. Surgery. 2001;130:443–8.PubMedCrossRef
14.
Zurück zum Zitat Sakuragawa N, Hasegawa H, Maki M, Nakagawa, Nakashima M. Clinical evaluation of low molecular weight heparin (FR-860) on disseminated intravascular coagulation (DIC)—a multicenter co-operative double-blind trial in comparison with heparin. Thromb Res. 1993;72:475–500.PubMedCrossRef Sakuragawa N, Hasegawa H, Maki M, Nakagawa, Nakashima M. Clinical evaluation of low molecular weight heparin (FR-860) on disseminated intravascular coagulation (DIC)—a multicenter co-operative double-blind trial in comparison with heparin. Thromb Res. 1993;72:475–500.PubMedCrossRef
15.
Zurück zum Zitat Aoki N, Yoshida M, Yamanaka T. Treatment of DIC with antithrombin III concentrate (in Japanese). Igakunoayumi. 1979;109:970–4 (in Japanese). Aoki N, Yoshida M, Yamanaka T. Treatment of DIC with antithrombin III concentrate (in Japanese). Igakunoayumi. 1979;109:970–4 (in Japanese).
16.
Zurück zum Zitat Clavien PA, Barkun J, de Oliveira ML, Vauthey JN, Dindo D, Schulick RD, et al. The Clavien–Dindo classification of surgical complications: five-year experience. Ann Surg. 2009;250:187–96.PubMedCrossRef Clavien PA, Barkun J, de Oliveira ML, Vauthey JN, Dindo D, Schulick RD, et al. The Clavien–Dindo classification of surgical complications: five-year experience. Ann Surg. 2009;250:187–96.PubMedCrossRef
17.
Zurück zum Zitat Zinsmeister AR, Connor JT. Ten common statistical errors and how to avoid them. Am J Gastroenterol. 2008;103:262–6.PubMedCrossRef Zinsmeister AR, Connor JT. Ten common statistical errors and how to avoid them. Am J Gastroenterol. 2008;103:262–6.PubMedCrossRef
18.
Zurück zum Zitat Layer P, Zinsmeister AR, DiMagno EP. Effects of decreasing intraluminal amylase activity on starch digestion and postprandial gastrointestinal function in humans. Gastroenterology. 1986;91:41–8.PubMed Layer P, Zinsmeister AR, DiMagno EP. Effects of decreasing intraluminal amylase activity on starch digestion and postprandial gastrointestinal function in humans. Gastroenterology. 1986;91:41–8.PubMed
19.
Zurück zum Zitat Rubin DB. Estimating causal effects from large data sets using propensity scores. Ann Intern Med. 1997;127:757–63.PubMed Rubin DB. Estimating causal effects from large data sets using propensity scores. Ann Intern Med. 1997;127:757–63.PubMed
20.
Zurück zum Zitat D’Agostino RB Jr. Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med. 1998;17:2265–81.PubMedCrossRef D’Agostino RB Jr. Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med. 1998;17:2265–81.PubMedCrossRef
21.
Zurück zum Zitat Kurata M, Okajima K, Kawamoto T, Uchiba M, Ohkochi N. Antithrombin reduces reperfusion-induced hepatic metastasis of colon cancer cells. World J Gastroenterol. 2006;12:60–5.PubMed Kurata M, Okajima K, Kawamoto T, Uchiba M, Ohkochi N. Antithrombin reduces reperfusion-induced hepatic metastasis of colon cancer cells. World J Gastroenterol. 2006;12:60–5.PubMed
22.
Zurück zum Zitat Meyer-Siegler KL, Cox J, Leng L, Bucala R, Vera PL. Macrophage migration inhibitory factor anti-thrombin III complex formation as a mechanism of inactivation. Cancer Lett. 2010;290:49–57.PubMedCrossRef Meyer-Siegler KL, Cox J, Leng L, Bucala R, Vera PL. Macrophage migration inhibitory factor anti-thrombin III complex formation as a mechanism of inactivation. Cancer Lett. 2010;290:49–57.PubMedCrossRef
23.
Zurück zum Zitat Hu L, Roth JM, Brooks P, Luty J, Karpatkin S. Thrombin up-regulates cathepsin D which enhances angiogenesis, growth, and metastasis. Cancer Res. 2008;68:4666–73.PubMedCrossRef Hu L, Roth JM, Brooks P, Luty J, Karpatkin S. Thrombin up-regulates cathepsin D which enhances angiogenesis, growth, and metastasis. Cancer Res. 2008;68:4666–73.PubMedCrossRef
24.
Zurück zum Zitat Hu L, Ibrahim S, Liu C, Skaar J, Pagano M, Karpatkin S. Thrombin induces tumor cell cycle activation and spontaneous growth by down-regulation of p27Kip1, in association with the up-regulation of skp2 and mir-222. Cancer Res. 2009;69:3374–81.PubMedCrossRef Hu L, Ibrahim S, Liu C, Skaar J, Pagano M, Karpatkin S. Thrombin induces tumor cell cycle activation and spontaneous growth by down-regulation of p27Kip1, in association with the up-regulation of skp2 and mir-222. Cancer Res. 2009;69:3374–81.PubMedCrossRef
25.
Zurück zum Zitat Hu L, Roth JM, Brooks P, Ibrahim S, Karpatkin S. Twist is required for thrombin-induced tumor angiogenesis and growth. Cancer Res. 2008;68:4296–302.PubMedCrossRef Hu L, Roth JM, Brooks P, Ibrahim S, Karpatkin S. Twist is required for thrombin-induced tumor angiogenesis and growth. Cancer Res. 2008;68:4296–302.PubMedCrossRef
26.
Zurück zum Zitat Kaufmann R, Rahn S, Pollrich K, Hertel J, Dittmar Y, Hommann M, et al. Thrombin-mediated hepatocellular carcinoma cell migration: cooperative action via proteinase-activated receptors 1 and 4. J Cell Physiol. 2007;211:699–707.PubMedCrossRef Kaufmann R, Rahn S, Pollrich K, Hertel J, Dittmar Y, Hommann M, et al. Thrombin-mediated hepatocellular carcinoma cell migration: cooperative action via proteinase-activated receptors 1 and 4. J Cell Physiol. 2007;211:699–707.PubMedCrossRef
27.
Zurück zum Zitat Rullier A, Senant N, Kisiel W, Bioulac-Sage P, Balabaud C, Bail BL, et al. Expression of protease-activated receptors and tissue factor in human liver. Virchows Arch. 2006;448:46–51.PubMedCrossRef Rullier A, Senant N, Kisiel W, Bioulac-Sage P, Balabaud C, Bail BL, et al. Expression of protease-activated receptors and tissue factor in human liver. Virchows Arch. 2006;448:46–51.PubMedCrossRef
28.
Zurück zum Zitat Takafuji V, Forgues M, Unsworth E, Goldsmith P, Wang XW. An osteopontin fragment for tumor cell invasion in hepatocellular carcinoma. Oncogene. 2007;26:6361–71.PubMedCrossRef Takafuji V, Forgues M, Unsworth E, Goldsmith P, Wang XW. An osteopontin fragment for tumor cell invasion in hepatocellular carcinoma. Oncogene. 2007;26:6361–71.PubMedCrossRef
29.
Zurück zum Zitat Korita PV, Wakai T, Shirai Y, Matsuda Y, Sakata J, Cui X, et al. Overexpression of osteopontin independently correlates with vascular invasion and poor prognosis in patients with hepatocellular carcinoma. Human Pathol. 2008;39:1777–83.CrossRef Korita PV, Wakai T, Shirai Y, Matsuda Y, Sakata J, Cui X, et al. Overexpression of osteopontin independently correlates with vascular invasion and poor prognosis in patients with hepatocellular carcinoma. Human Pathol. 2008;39:1777–83.CrossRef
30.
Zurück zum Zitat Mi Z, Oliver T, Guo H, Kuo PC. Thrombin-cleaved COOH(−) terminal osteopontin peptide binds with cyclophilin C to CD147 in murine breast cancer cells. Cancer Res. 2007;67:4088–97.PubMedCrossRef Mi Z, Oliver T, Guo H, Kuo PC. Thrombin-cleaved COOH(−) terminal osteopontin peptide binds with cyclophilin C to CD147 in murine breast cancer cells. Cancer Res. 2007;67:4088–97.PubMedCrossRef
31.
Zurück zum Zitat Xue YH, Zhang QZ, Sun J, Dai C, Zhou HJ, Ren N, et al. Thrombin is a therapeutic target for metastatic osteopontin-positive hepatocellular carcinoma. Hepatology. 2010;52:2012–22.PubMedCrossRef Xue YH, Zhang QZ, Sun J, Dai C, Zhou HJ, Ren N, et al. Thrombin is a therapeutic target for metastatic osteopontin-positive hepatocellular carcinoma. Hepatology. 2010;52:2012–22.PubMedCrossRef
32.
Zurück zum Zitat Shimada M, Takenaka K, Taguchi K, Fujiwara Y, Gion T, Kajiyama K, et al. Prognostic factors after repeat hepatectomy for recurrent hepatocellular carcinoma. Ann Surg. 1998;227:80–5.PubMedCrossRef Shimada M, Takenaka K, Taguchi K, Fujiwara Y, Gion T, Kajiyama K, et al. Prognostic factors after repeat hepatectomy for recurrent hepatocellular carcinoma. Ann Surg. 1998;227:80–5.PubMedCrossRef
33.
Zurück zum Zitat Minagawa M, Makuuchi M, Takayama T, Kokudo N. Selection criteria for repeat hepatectomy in patients with recurrent hepatocellular carcinoma. Ann Surg. 2003;238:703–10.PubMedCrossRef Minagawa M, Makuuchi M, Takayama T, Kokudo N. Selection criteria for repeat hepatectomy in patients with recurrent hepatocellular carcinoma. Ann Surg. 2003;238:703–10.PubMedCrossRef
34.
Zurück zum Zitat Poon RTP, Fan ST, Lo CM, Liu CL, Wong J. Intrahepatic recurrence after curative resection of hepatocellular carcinoma; long-term results of treatment and prognostic factors. Ann Surg. 1999;229:216–22.PubMedCrossRef Poon RTP, Fan ST, Lo CM, Liu CL, Wong J. Intrahepatic recurrence after curative resection of hepatocellular carcinoma; long-term results of treatment and prognostic factors. Ann Surg. 1999;229:216–22.PubMedCrossRef
35.
Zurück zum Zitat Hanazaki K, Kajikawa S, Shimozawa N, Mihara M, Shimada K, Hiraguchi M, et al. Survival and recurrence after hepatic resection of 386 consecutive patients with hepatocellular carcinoma. J Am Coll Surg. 2000;191:381–8.PubMedCrossRef Hanazaki K, Kajikawa S, Shimozawa N, Mihara M, Shimada K, Hiraguchi M, et al. Survival and recurrence after hepatic resection of 386 consecutive patients with hepatocellular carcinoma. J Am Coll Surg. 2000;191:381–8.PubMedCrossRef
Metadaten
Titel
Prognostic Significance of Antithrombin III Levels for Outcomes in Patients with Hepatocellular Carcinoma After Curative Hepatectomy
verfasst von
Hiroshi Iwako, MD
Hirotaka Tashiro, MD
Hironobu Amano, MD
Yoshisato Tanimoto, MD
Akihiko Oshita, MD
Tsuyoshi Kobayashi, MD
Shintaro Kuroda, MD
Hirofumi Tazawa, MD
Junko Nambu, MD
Yoshihiro Mikuriya, MD
Tomoyuki Abe, MD
Hideki Ohdan, MD
Publikationsdatum
01.09.2012
Verlag
Springer-Verlag
Erschienen in
Annals of Surgical Oncology / Ausgabe 9/2012
Print ISSN: 1068-9265
Elektronische ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-012-2338-y

Weitere Artikel der Ausgabe 9/2012

Annals of Surgical Oncology 9/2012 Zur Ausgabe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.